在心力衰竭的演变过程中,第一阶段喷射分数的时间变化与保存的喷射分数和后负载诱导的心力衰竭在小鼠中
Haotian Gu1, Norman Catibog1, Yue Zhao1
1School of Cardiovascular and Metabolic Medicine & Sciences, King's College London BHF Centre of Research Excellence, 125 Coldharbour Lane, London, SE5 9NU, UK.
Journal of physiology and biochemistry
|February 4, 2026
概括
第一阶段喷射分数 (EF1) 在心力衰竭早期随着保留喷射分数 (HFpEF) 和后负载诱导的功能障碍而下降,先于其他缩变化并与腹功能障碍相吻合. 左心房扩大发生在HFpEF进展的晚期.
科学领域:
- 心脏病学 心脏病学
- 身体生理学 身体生理学
- 病理生理学 病理生理学
背景情况:
- 心力衰竭与保留喷射分数 (HFpEF) 的进展涉及复杂的静脉缩和静脉缩功能障碍相互作用.
- 第一阶段喷射分数 (EF1) 是静缩功能的一个敏感的早期指标,有助于评估静缩-透缩关系.
研究的目的:
- 在HFpEF和升高后负载的小鼠模型中研究缩和扩散功能障碍之间的时间关系.
- 评估EF1在这些条件下作为早期标记物的实用性.
主要方法:
- 在腹腔大动脉带 (AAB) 和HFpEF (高血压和高脂肪饮食) 的小鼠模型中利用序列回声心脏学.
- 测量EF1,射出分数 (EF),全球纵向应变 (GLS),纵向应变率 (LSR),异体放松时间 (IVRT) 和左心房 (LA) 尺寸.
主要成果:
- 在AAB中,EF1在第1周显著下降,而EF,GLS和LSR直到第3周保持不变. IVRT是最早出现的腹筋异常.
- 在HFpEF模型中,EF1在第2周下降,随后在第3周减少GLS. IVRT 较早增加,LA 扩大较晚发生.
- 在这两种模型中,EF1降低始终在其他缩性损伤之前,并与早期的透缩功能障碍 (IVRT延长) 相吻合.
结论:
- 早期的缩性损伤,以EF1降低为标志,在HFpEF中与腹功能障碍和后负载诱导的心脏功能障碍同时发生.
- 左心房扩大是HFpEF进展的晚期表现.
- 这些发现阐明了在HFpEF病变发生过程中缩和腹功能障碍之间的相互作用.
相关概念视频
01:29Heart Failure II: Pathophysiology
952
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
952
01:17Pathophysiology of Heart Failure
3.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.8K
01:27Heart Failure I: Introduction
903
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
903
01:22Heart Failure VI: Adjunct Therapies
348
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
348
01:22Heart Failure Drugs: Diuretics
983
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
983
01:30Heart Failure V: Medical Management
330
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
330